{
    "2018-09-04": [
        [
            {
                "time": "2018-07-01",
                "original_text": "Insurance tactic drags down U.S. drug prices in 2nd qtr -analyst",
                "features": {
                    "keywords": [
                        "Insurance",
                        "tactic",
                        "drags",
                        "down",
                        "U.S.",
                        "drug",
                        "prices"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-07-02",
                "original_text": "Novo Nordisk's Ozempic Lowers Risk of Cardiovascular Events (revised)",
                "features": {
                    "keywords": [
                        "Novo",
                        "Nordisk",
                        "Ozempic",
                        "Lowers",
                        "Risk",
                        "Cardiovascular",
                        "Events"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-07-03",
                "original_text": "Insurance tactic drags down U.S. drug prices in 2nd quarter -analyst",
                "features": {
                    "keywords": [
                        "Insurance",
                        "tactic",
                        "drags",
                        "down",
                        "U.S.",
                        "drug",
                        "prices"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-07-04",
                "original_text": "AstraZeneca Up This Year So Far on Favorable Pipeline Updates",
                "features": {
                    "keywords": [
                        "AstraZeneca",
                        "Up",
                        "Favorable",
                        "Pipeline",
                        "Updates"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-07-05",
                "original_text": "Better Buy: Pfizer Inc. vs. Eli Lilly and Company",
                "features": {
                    "keywords": [
                        "Better",
                        "Buy",
                        "Pfizer",
                        "Eli",
                        "Lilly"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-07-06",
                "original_text": "WisdomTree U.S. LargeCap Dividend Fund -- Insider Buying Index Registering 12.1%",
                "features": {
                    "keywords": [
                        "WisdomTree",
                        "U.S.",
                        "LargeCap",
                        "Dividend",
                        "Fund",
                        "Insider",
                        "Buying",
                        "Index"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "finance",
                        "dividends"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-07-07",
                "original_text": "How Eli Lilly’s Elanco Performed in Q2 2018",
                "features": {
                    "keywords": [
                        "Eli",
                        "Lilly",
                        "Elanco",
                        "Performed",
                        "Q2",
                        "2018"
                    ],
                    "sentiment_score": 0.4,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-07-08",
                "original_text": "A Look at Eli Lilly’s Neuroscience Products in Q2 2018",
                "features": {
                    "keywords": [
                        "Eli",
                        "Lilly",
                        "Neuroscience",
                        "Products",
                        "Q2",
                        "2018"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}